caa a22 4500 445888423 CHVBK 20180317145607.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1007/s00535-010-0342-1 doi (NATIONALLICENCE)springer-10.1007/s00535-010-0342-1 Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan [Elektronische Daten] [Michio Hongo, Hiroto Miwa, Motoyasu Kusano] Background: Despite many reports from Western nations describing endoscopic and symptomatic improvements in patients with reflux esophagitis (RE) using proton pump inhibitors (PPI), PPI effects on the health-related quality of life (HRQOL), particularly for a dose duration of less than 8weeks, have not been sufficiently clarified in Japanese RE patients. Methods: RE patients (n=9,029) in general practice settings took rabeprazole once daily for 8weeks. HRQOL, using the 8-item Short-Form Health Survey (SF-8™), and symptoms, using a frequency scale for the symptoms of gastroesophageal reflux disease (GERD), were evaluated at the initiation of therapy (0W), week 4 (4W), and week 8 (8W). Endoscopy was performed at 0 and 8W where possible. Results: In efficacy analysis (n=6,839), the mean±SD values for the physical component summary of the SF-8™ at 0, 4, and 8W were 45.005±7.534, 48.517±6.336, and 49.328±6.207, respectively, while those for the mental component summary were 46.465±7.743, 49.460±6.470, and 50.388±6.049, respectively. Significant improvements, compared to 0W, were observed in eight domains and two summary scores at 4W (P<0.001), and further QOL score elevations were seen by 8W. Regarding symptoms, the mean total frequency scale for the symptoms of GERD (FSSG) scores at 0, 4, and 8W were 16.4±9.8, 7.8±7.4, and 6.0±6.8, respectively. Significant improvements, compared to 0W, were seen in the total, reflux, and dysmotility scores and in the scores for all 12 items at 4W (P<0.001). Conclusions: The score for the HRQOL of RE patients before rabeprazole therapy was below 50 points (the national mean for the general Japanese population), indicating harmed QOL. Rabeprazole markedly improved the HRQOL at 4W, with recovery to the national mean by 8W. Symptoms had also improved significantly at 4W, with further improvements observed at 8W. Springer, 2010 Rabeprazole nationallicence Reflux esophagitis nationallicence Quality of life nationallicence Symptoms nationallicence Hongo Michio Department of Comprehensive Medicine and Psychosomatic Medicine, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba, 980-8574, Sendai, Miyagi, Japan aut Miwa Hiroto Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan aut Kusano Motoyasu Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Maebashi, Japan aut Journal of Gastroenterology Springer Japan 46/3(2011-03-01), 297-304 0944-1174 46:3<297 2011 46 535 https://doi.org/10.1007/s00535-010-0342-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00535-010-0342-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hongo Michio Department of Comprehensive Medicine and Psychosomatic Medicine, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba, 980-8574, Sendai, Miyagi, Japan aut NATIONALLICENCE 700 1- Miwa Hiroto Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan aut NATIONALLICENCE 700 1- Kusano Motoyasu Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Maebashi, Japan aut NATIONALLICENCE 773 0- Journal of Gastroenterology Springer Japan 46/3(2011-03-01), 297-304 0944-1174 46:3<297 2011 46 535 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer